Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × ALK+ Advanced NSCLC × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1000 Carcinoma, Non-Small-Cell Lung 627 Neoplasms 490 Prostatic Neoplasms 450 Colorectal Neoplasms 385 Multiple Myeloma 296 Lung Neoplasms 270 Neoplasm Metastasis 262 Leukemia, Myeloid, Acute 234 Carcinoma, Hepatocellular 228 Stomach Neoplasms 220 Ovarian Neoplasms 196 Rectal Neoplasms 189 Lymphoma 182 Colonic Neoplasms 180 Lymphoma, Follicular 179 Leukemia 168 Uterine Cervical Neoplasms 161 Pancreatic Neoplasms 156 Lymphoma, Non-Hodgkin 152 Head and Neck Neoplasms 151 Lymphoma, Large B-Cell, Diffuse 148 Recurrence 147 Leukemia, Lymphocytic, Chronic, B-Cell 144 Precursor Cell Lymphoblastic Leukemia-Lymphoma 139 Melanoma 137 Brain Neoplasms 127 Urinary Bladder Neoplasms 126 Pain 124 Squamous Cell Carcinoma of Head and Neck 123

Interventions

brigatinib 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03596866 2025-09-12

ALTA-3

Takeda

Phase 3 Completed

248 enrolled 20 charts

ALK+ Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡